The prostate cancer continuum: The role of bicalutamide (Casodex®)

Prostate Journal

Volumn 3, Issue 1, 2001, Pages 2-13

  Kolvenbag, G J C M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

BACKACHE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONSTIPATION; DRUG INDUCED DISEASE; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MASTALGIA; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW;

EID: 0034856927     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2001.003001002.x     Document Type: Review

References (73)

1. The epidemiology and prevention of prostate cancer
2. The TNM classification of prostate cancer
3. The present status of radical prostatectomy for s tages A and B prostatic cancer
4. Proposed substages for metastatic prostate cancer
5. The current and future role of non-steroidal antiandrogen in the treatment of prostate cancer
6. Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia
7. Prevalence of prostatic intraepithelial (PIN) in surgical resections
8. Prostatic intraepithelial neoplasia in surgical resections: Relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate
9. Orchidectomy and oestrogen therapy revisited
10. Goserelin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
11. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial: Zoladex Prostate Study Group
12. Advantages of total androgen blockade in the treatment of advanced prostate cancer
13. New concepts on the androgen sensitivity of prostate cancer
14. Epidemiology of prostate cancer
15. Normal range prostate-specific antigen versus age-specific antigen in screening prostate adenocarcinoma
16. Familial prostate cancer in Sweden: A nationwide register cohort study
17. Family history and prostate cancer risk
18. Familial aspects of prostate cancer: A case control study
19. Hereditary aspects of prostate cancer
20. Mortality in prostate cancer
21. Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer
22. Reference ranges for serum prostate-specific antigen in black and white men without cancer
23. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues
24. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy
25. Management of cancer of the prostate
26. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
27. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 prostate cancer
28. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy
29. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
30. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
31. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
32. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy
33. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
34. Randomised multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery
35. Immediate hormonal therapy versus observation for node positive prostate cancer following radical prostatectomy and pelvic lymph adenectomy: A randomized Phase III Eastern Cooperative Oncology Group trial
36. Randomised comparative study of 3 versus 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: Biochemical and pathological effects
37. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-T3 NO MO prostatic carcinoma: The European Study Group on Neoadjuvant Treatment of Prostate Cancer
38. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer
39. Adjuvant hormone therapy after radical prostatectomy: Indications and results
40. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
41. Serum PSA after antiandrogen therapy
42. Prostate specific antigen and local recurrence after radical prostatectomy
43. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound
44. Evaluation and management of men whose radical prostatectomies failed: Results of an international survey
45. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
46. Bicalutamide dosages used in the treatment of prostate cancer
47. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
48. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years
49. Bicalutamide ('Casodex') 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years' follow-up
50. Quality of life issues relating to endocrine treatment options
51. Waning sexual function: The most important disease-specific distress for patients with prostate cancer
52. Sex or survival: Trade-offs between quality and quantity of life
53. Patient preferences: Survival versus quality of life considerations
54. Osteoporosis after orchiectomy for prostate cancer
55. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
56. Casodex: Preclinical studies
57. Role of prostate-specific antigen as a predictor of outcome in prostate cancer
58. A randomised comparison of monotherapy with 'Casodex' 50 mg daily and castration in the treatment of metastatic prostate carcinoma
59. Single agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
60. Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer: The Scandinavian Casodex Cooperative Group
61. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial
62. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
63. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
64. Bicalutamide and flutamide, each in combination with LHRH analogs, in advanced prostate cancer: Exploratory analysis of impact of extent of disease by bone scan on outcome
65. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer
66. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer
67. Does prolonged combined androgen blockade have survival benefits over short term CAB therapy?
68. An open multicentre randomised study to compare the effect and safety of 'Casodex' (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer
69. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian prostate cancer project (PONCAP) study
70. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
71. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
72. Phase II trial of Casodex in advanced prostate cancer (CAP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study (SWOG 9235)